Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04262843 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

StatusActive, Not Recruiting
PhasePhase 2
Started2020-02-07
View on ClinicalTrials.gov ↗
This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal organs and graft-versus-host disease (a complication after transplantation in which donor's immune cells recognize the host as foreign and attack the recipient's tissues). Total body irradiation is a form of radiotherapy that involves irradiating the patient's entire body in an attempt to suppress the immune system, prevent rejection of the transplanted bone marrow and/or stem cells and to wipe out any remaining cancer cells. Intensity-modulated radiation therapy (IMRT) is a more recently developed method of delivering radiation. Total marrow and lymphoid irradiation is a method of using IMRT to direct radiation to the bone marrow. Total marrow and lymphoid irradiation may allow a greater dose of radiation to be delivered to the bone marrow as a preparative regimen before hematopoietic cell transplant while causing less side effects to normal organs than standard total body irradiation.

Amendment history 2 changes detected by DataLookout

2026-09-02
critical
Primary completion pushed: 2026-06-23 → 2027-05-11
2026-09-02
minor
Completion pushed: 2026-06-23 → 2027-05-11
Trial Details
NCT Number NCT04262843
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
Enrollment 33 participants
Start Date 2020-02-07
Primary Completion 2027-05-11 (estimated)
Study Completion 2027-05-11 (estimated)
Updated on ClinicalTrials.gov 2026-09-01